Evaluation of Early Home Return in Patients With Enucleation of Prostate Adenoma

Launched by GCS RAMSAY SANTÉ POUR L'ENSEIGNEMENT ET LA RECHERCHE · Jun 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help men with prostate adenoma, which is a non-cancerous enlargement of the prostate. Traditionally, patients undergoing surgery to remove this condition typically stay in the hospital for at least 48 hours. However, the Union Clinique has created a care plan that aims to reduce this hospital stay to just one night, allowing patients to return home more quickly while still being monitored by nurses. The goal is to see if this method can be safely used in other healthcare facilities without increasing the risk of serious complications for patients.

To be eligible for the trial, participants must be male patients scheduled for laser surgery to treat their prostate adenoma. They should be experiencing symptoms that haven't improved with medication or have specific complications related to their condition. Participants can expect to have their surgery and then return home the next day, with support from healthcare professionals to ensure their recovery goes smoothly. This trial is currently recruiting participants, and it could provide valuable insights into improving recovery times for men undergoing this type of surgery.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patient planned for endoscopic enucleation of prostate adenoma with laser
• • Patient with symptomatic benign prostatic hyperplasia and refractory to medical reatment and/or
• • Patient with benign prostatic hyperplasia complicated by chronic retention of urine and/or
• • Patient with benign prostatic hyperplasia complicated by prostatitis and/or
• • Patient with symptomatic benign prostatic hyperplasia
• Exclusion Criteria:
• • Patient living beyond the scope of care by the nurses coordination
• • Bedridden patient or WHO clinical condition \>2
• • Patient requiring curative anticoagulation which cannot be interrupted or relayed at home by heparin
• • Patient with double anti-platelet aggregation who cannot be interrupted